HaemaLogiX to present final data from anti-KMA CAR-T preclinical studies at AACR
- Written by PR Newswire
SYDNEY, March 28, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage biotech company developing novel immunotherapies for multiple myeloma, today announced that its anti-KMA CAR-T cell preclinical development has been completed and is the subject of an abstract accepted for poster presentation at the 2023 Annual Meeting of the American...







